MAIA raises $33M to fully fund pivotal Phase 3 cancer therapy trial

Filed April 8, 2026 · Period ending April 8, 2026 · ~1 min read

Key Changes

• high

  Company secured $33 million in new capital, which management expects will fully cover costs of its ongoing pivotal Phase 3 clinical trial for telomere-targeting anticancer therapy through completion.

  8-K: Press Release verify on EDGAR →
• high

  Funding provides clear runway for lead clinical program, eliminating near-term dilution risk for the Phase 3 trial and reducing execution uncertainty around the company's most important value driver.

  8-K: Capital Raise verify on EDGAR →